Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects

Metabolism: Clinical and Experimental

Volumn 58, Issue 7, 2009, Pages 946-953

  Madsen, Erik L ^a   Bruun, Jens M ^a   Skogstrand, Kristin ^b   Hougaard, David M ^b   Christiansen, Tore ^a   Richelsen, Bjørn ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; INTERLEUKIN 18; LEPTIN; LIPID; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FLOW MEASUREMENT; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOW CALORY DIET; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; BLOOD PRESSURE; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-18; LACTONES; LEPTIN; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OBESITY; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT LOSS; YOUNG ADULT;

EID: 66349096555     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.02.031     Document Type: Article

References (53)

1. Chan J.C., Cheung J.C., Stehouwer C.D., et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome-an analysis by structural equation modelling. Int J Obes Relat Metab Disord 26 (2002) 994-1008
2. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3413-3421
3. Yusuf S., Hawken S., Ounpuu S., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366 (2005) 1640-1649
4. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
5. Woo K.S., Chook P., Yu C.W., et al. Overweight in children is associated with arterial endothelial dysfunction and intima-media thickening. Int J Obes Relat Metab Disord 28 (2004) 852-857
6. Yudkin J.S., Kumari M., Humphries S.E., et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
7. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11 (2003) 1278-1289
8. Skurk T., berti-Huber C., Herder C., et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92 (2007) 1023-1033
9. Bruun J.M., Lihn A.S., Pedersen S.B., et al. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 90 (2005) 2282-2289
10. Fain J.N., Madan A.K., Hiler M.L., et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
11. Gillespie M.T., and Horwood N.J. Interleukin-18: perspectives on the newest interleukin. Cytokine Growth Factor Rev 9 (1998) 109-116
12. Bruun J.M., Stallknecht B., Helge J.W., et al. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 157 (2007) 465-471
13. Esposito K., Pontillo A., Ciotola M., et al. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87 (2002) 3864-3866
14. Schernthaner G.H., Kopp H.P., Kriwanek S., et al. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes Surg 16 (2006) 709-715
15. Leick L., Lindegaard B., Stensvold D., et al. Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise. Obes Res 15 (2007) 356-363
16. Blankenberg S., Tiret L., Bickel C., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106 (2002) 24-30
17. Mallat Z., Corbaz A., Scoazec A., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89 (2001) 41e-445e
18. Mallat Z., Corbaz A., Scoazec A., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104 (2001) 1598-1603
19. Dinarello C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 83 (2006) 447S-455S
20. Fain J.N., Tichansky D.S., and Madan A.K. Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism 55 (2006) 1113-1121
21. Clement K., Viguerie N., Poitou C., et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18 (2004) 1657-1669
22. Nold M., Goede A., Eberhardt W., et al. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 68-75
23. Tayebjee M.H., Nadar S., Blann A.D., et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17 (2004) 764-769
24. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
25. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
26. Glowinska-Olszewska B., and Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 56 (2007) 799-805
27. Laimer M., Kaser S., Kranebitter M., et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes Relat Metab Disord 29 (2005) 498-501
28. Bouloumie A., Sengenes C., Portolan G., et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 50 (2001) 2080-2086
29. Park H.Y., Kwon H.M., Lim H.J., et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33 (2001) 95-102
30. Richelsen B., Tonstad S., Rossner S., et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 30 (2007) 27-32
31. Madsen E.L., Rissanen A., Bruun J.M., et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 158 (2008) 179-187
32. Skogstrand K., Thorsen P., Norgaard-Pedersen B., et al. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 51 (2005) 1854-1866
33. Wilson P.W.F., D'Agostino R.B., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162 (2002) 1867-1872
34. Tzoulaki I., Murray G.D., Lee A.J., et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh artery study. Circulation 115 (2007) 2119-2127
35. Kapiotis S., Holzer G., Schaller G., et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol 26 (2006) 2541-2546
36. Haffner S.M. Abdominal adiposity and cardiometabolic risk: do we have all the answers?. Am J Med 120 Suppl 1 (2007) S10-S16
37. Hung J., McQuillan B.M., Chapman C.M.L., et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 25 (2005) 1268-1273
38. Thorand B., Kolb H., Baumert J., et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetes 54 (2005) 2932-2938
39. Araki S., Haneda M., Koya D., et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 50 (2007) 867-873
40. Kelley D.E., Kuller L.H., McKolanis T.M., et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27 (2004) 33-40
41. Bougoulia M., Triantos A., and Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 5 (2006) 259-269
42. Evans J., Collins M., Jennings C., et al. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol 157 (2007) 633-640
43. Herder C., Schneitler S., Rathmann W., et al. Low-grade inflammation, obesity and insulin resistance in adolescents. J Clin Endocrinol Metab 92 (2007) 4569-4574
44. Kim H.J., Kang E.S., Kim D.J., et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66 (2007) 282-289
45. Herder C., Baumert J., Kolb H., et al. Circulating levels of interleukin-18 independent of body fat and fat-free mass: results from the MONICA/KORA study. Diabetes Care 29 (2006) 174-175
46. Vilarrasa N., Vendrell J., Maravall J., et al. IL-18: relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res 38 (2006) 507-512
47. Chapman C.M.L., McQuillan B.M., Beilby J.P., et al. Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population: the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Atherosclerosis 189 (2006) 414-419
48. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 (2003) 1799-1804
49. Marfella R., Esposito K., Siniscalchi M., et al. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 27 (2004) 47-52
50. Korner J., Bessler M., Inabnet W., et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3 (2007) 597-601
51. Faggioni R., Jones-Carson J., Reed D.A., et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 97 (2000) 2367-2372
52. Salas-Salvadó J., Bulló M., García-Lorda P., et al. Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss. Int J Obes (Lond) 30 (2006) 1714-1720
53. Warner R.L., Bhagavathula N., Nerusu K.C., et al. Matrix metalloproteinases in acute inflammation: induction of MMP-3 and MMP-9 in fibroblasts and epithelial cells following exposure to pro-inflammatory mediators in vitro. Exp Mol Pathol 76 (2004) 189-195